Phase 2
Completed N=170
Toradol v. Celecoxib for Postoperative Pain
Pain, Postoperative
Source: ClinicalTrials.gov NCT03331315 ↗
Enrolled (actual)
170
Serious AEs
0.0%
Results posted
Jun 2018
Primary outcomePrimary: Average Inpatient Postoperative Pain Score — 2.7; 2.4 units on a scale
Summary
Randomized control trial between ketorolac versus celecoxib for postoperative pain following hysterectomy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Inpatient Postoperative Pain Score |
2.7; 2.4 | — |
| SECONDARY Average Inpatient Hydromorphone Use |
0.7; 0.8 | — |
| SECONDARY Average Inpatient Ondansetron Use |
1.5; 1.3 | — |
| SECONDARY Total Hospital Stay |
11.6; 11.9 | — |
| SECONDARY Number of Participants With Perioperative Complications |
5; 6 | — |
| SECONDARY Return to Activities of Daily Living |
2.4; 2.2 | — |
| SECONDARY Days of Oral Narcotic Use After Discharge |
5.7; 3.8 | — |
| SECONDARY Number of Oral Narcotic Pills Used After Discharge |
8.1; 6.0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients undergoing hysterectomy
Exclusion Criteria
- Coronary Artery Disease
- Peptic Ulcer Disease
- Chronic Renal Disease
- Liver disease
- Alcohol Abuse
- Daily narcotic usage
- Narcotic use 24 hours prior to surgery
- Crohn's Disease
- History of myocardial infarction
- History of stroke
- Preoperative hematocrit less than 24
- Asthma
- Ulcerative Colitis
- Diverticulitis
- Aspirin Allergy
- Sulfonamide Allergy
- Pre-operative pain score of greater than 3
- Patients undergoing procedures that may involve bowel resection or bowel reanastomosis.
- Allergy to any non-steroidal anti-inflammatory drug
- Cardiac anomaly or disease
- Congestive Heart Failure
Data sourced from ClinicalTrials.gov (NCT03331315). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.